// App-Quantinova.ai

: A HIGHER DOSE OF DASATINIB MAY INCREASE THE POSSIBILITY OF CROSSING THE BLOOD-BRAIN BARRIER IN THE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Xiaoyuan Gong

Principal Investigators

  • Ying Wang

  • Guangji Zhang

  • Chunlin Zhou

  • Kaiqi Liu

  • Dong Lin

  • Bingcheng Liu

  • Hui Wei

  • Shuning Wei

  • Yan Li

  • Benfa Gong

  • Yuntao Liu

  • Runxia Gu

  • Shaowei Qiu

  • Yingchang Mi

  • Jianxiang Wang

Medical Centers

  • State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cerebrospinal fluid

Drug/Treatment

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02523976

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved